Schwartz Jeffrey Lawrence Form 4 RAPID MICRO BIOSYSTEMS / Jeffrey Lawrence Schwartz ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Schwartz Jeffrey Lawrence

(Last) (First) (Middle)

C/O BAIN CAPITAL LIFE SCIENCES INVESTORS

200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPID MICRO BIOSYSTEMS, INC. [ RPID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/23/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/23/2024		A		14,300(1)	A	$0.00	14,300	D
Class A Common Stock								8,434,560	I	See footnotes(3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.82	05/23/2024		A		28,650		(2)	05/22/2034	Class A Common Stock	28,650	$0.00	28,650	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date.

2. The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date.

3. Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS Fund I") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS Fund I, the "Bain Capital Life Sciences Entities").

4. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS Fund I and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Mr. Schwartz is a Partner of BCLSI. By virtue of the relationships described in this footnote, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Jeffrey Schwartz	05/28/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.